Study of two drugs for post-transplant lymphoma
Treatments studied
Part of Cancer, Immune system & allergy clinical trials.
This study tests a combination of two medications, loncastuximab tesirine and rituximab, as the first treatment for a type of lymphoma that can develop after an organ transplant. The goal is to see if this combination is safe and effective at shrinking or eliminating the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have been diagnosed with a specific type of B-cell lymphoma that developed after a solid organ transplant (like kidney, liver, heart, etc.).
- Your cancer must be measurable on a scan (like a PET or CT scan).
- You must be physically able to perform daily activities (ECOG score of 2 or less).
- Your blood counts, liver, and kidney function must be within acceptable levels.
- You must not have received any previous treatment for this lymphoma, except for radiation, steroids, antivirals, or reducing your anti-rejection medications.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies tafasitamab plus rituximab to treat a type of lymphoma called post-transplant lymphoproliferative disorder (PTLD) in adults after a solid organ transplant. It’s aimed at helping stop the PTLD when it can be measured and before you’ve had PTLD treatment beyond limited measures like steroid or reducing anti-rejection drugs.
This trial tests whether a drug called rituximab can prevent a type of cancer called PTLD in people who have had an organ transplant and are showing signs of an EBV infection. EBV is a common virus that can be more dangerous for transplant patients, and this study aims to see if using rituximab early can stop PTLD from developing.
This study tests a new combination of two drugs—loncastuximab tesirine (an antibody-drug conjugate) and epcoritamab (a bispecific antibody)—for people whose aggressive B-cell lymphoma has returned or not responded to prior treatment. The goal is to see if the combination is safe and effective.
This study tests a drug called epcoritamab for people who have a type of lymphoma that developed after an organ transplant and has not responded to standard treatment. The drug aims to help your immune system fight the cancer cells.
This Phase 2 study tests whether loncastuximab, combined with rituximab, can shrink and control follicular lymphoma that has come back or not responded to prior treatment. It may help people who still have active disease that needs treatment and meet specific scan and blood test requirements.
This study tests an experimental drug for people with B-cell non-Hodgkin lymphoma (a type of blood cancer) that has come back or hasn't responded to standard treatments. The goal is to see if the drug is safe and can shrink the cancer.
Hear when a new Post-Transplant Lymphoproliferative Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.